Navigation Links
NIH extends commitment to transformative research with 2008 Pioneer, New Innovator Awards
Date:9/21/2008

Md., campus.

The recipients'names, institutions, and research plans are listed below.

For both programs, NIH selects the recipients through special application and evaluation processes. Distinguished outside experts identify the most highly competitive applicants. The Advisory Committee to the Director, NIH, performs the second level of review and Zerhouni makes final decisions based on the outside evaluations and programmatic considerations.

"These nontraditional application and review processes are serving as models in our efforts to enhance the NIH peer review system so that we can fund the best science, by the best scientists, while reducing the administrative burden for both applicants and reviewers," Zerhouni said.

Biographical sketches of the new Pioneer Award recipients are at http://nihroadmap.nih.gov/pioneer/Recipients08.aspx. The symposium agenda is at http://nihroadmap.nih.gov/pioneer/symposium2008. More information on the Pioneer Award, including details on the 47 scientists who received awards in the first four years of the program, is at http://nihroadmap.nih.gov/pioneer.

Information on the New Innovator Award is at http://nihroadmap.nih.gov/newinnovator. Details on the research plans of the new recipients are at http://nihroadmap.nih.gov/newinnovator/Recipients08.asp.

The NIH Roadmap for Medical Research, launched in 2004, is a series of initiatives designed to address fundamental knowledge gaps, develop transformative tools and technologies, and/or foster innovative approaches to complex problems. Funded through the NIH Common Fund, these programs cut across the missions of individual NIH Institutes and Centers (ICs) and are intended to accelera
'/>"/>

Contact: Ann Dieffenbach
dieffena@nigms.nih.gov
301-496-7301
NIH/National Institute of General Medical Sciences
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8 9

Related biology news :

1. DOE JGI extends the capabilities of the Integrated Microbial Genome System
2. Successful cooperation extends Dragon Program
3. Thinking makes it so: Science extends reach of prosthetic arms
4. FIJI Water announces sustainable growth initiative with commitment to help mitigate climate change
5. U of M researchers identify gene linked to common ailment in labrador retrievers
6. Friendly bacteria protect against type 1 diabetes, Yale researchers find
7. Life Sciences Discovery Fund advances latest research proposals
8. Using novel tool, UD researchers dig through cell trash and find treasure
9. Longevity, cancer and diet connected: New research in worms could apply to humans
10. Research pushes back history of crop development 10,000 years
11. Nanotechnology: A brave new world requires bold new research approaches
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Warwick research finds , Gamblers show the same ... research has shown. , Researchers, led by Dr Elliot ... conducted tests that found that both human gamblers and ... than low-value rewards. , Published in Biology Letters ... the important role that memories of previous biggest wins ...
(Date:8/26/2014)... over a colony of harmful bacteria, biofilms make ... protected in a biofilm pose a significant health ... to treatment, and biofilm-protected bacteria account for some ... and are 50 to 1,000 times more resistant ... essence, we may have stumbled onto a magic ...
(Date:8/26/2014)... In recent years, increasing pressure from policymakers, consumers, ... targets that go beyond reducing the pollutants they ... and lakes. Today companies must also assess environmental ... the mining of primary materials to the use ... has given rise to the discipline known as ...
Breaking Biology News(10 mins):Gamblers are greedy bird-brains, University of Warwick research finds 2Breakthrough antibacterial approach could resolve serious skin infections 2Breakthrough antibacterial approach could resolve serious skin infections 3Yale journal explores advances in sustainable manufacturing 2
... Candida albicans inconspicuously lives in our bodies until it ... go on the offensive. The fungus, known for causing yeast ... as candidemia in immunocompromised patients. An in vivo study, published ... can distinguish between a healthy and an unhealthy host and ...
... The northern spotted owl, a threatened species in ... run from active management of the forest lands that ... stand-replacing fire, researchers conclude in a recent study. ... or other fuel reduction activities in areas with high ...
... Antarctic Program Blue Ribbon Panel, commissioned by the ... (OSTP) and the National Science Foundation (NSF) released ... through Increased Logistical Effectiveness. The report is a ... containing numerous specific recommendations for the U.S. logistics ...
Cached Biology News:How a common fungus knows when to attack 2Active forest management to reduce fire could help protect northern spotted owl 2Blue Ribbon Panel unveils findings on logistical improvements to support Antarctic science 2
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com ... available in its catalogue: Global Chelating ... About Chelating Agent A chelating ... covalent bonds with metal ions, thereby forming a ... some metal-ions have on chemical processes, formulations, and ...
(Date:8/27/2014)... Aug. 27, 2014  Lisa Kulik saw fireworks for ... 4 holiday, thanks to a groundbreaking retinal implant co-invented ... renowned clinician-researcher at the University of Southern California (USC) ... Peoria, Ariz. resident who has retinitis ... of sight. On June 2, she became the first ...
(Date:8/27/2014)... “We are honored to be named to ... CEO of Radiant Sage. “We are offering truly ground-breaking ... corelab market to a different level. We are ... efficiently and effectively manage the massive amounts of medical ... and read by trained physicians. Being recognized by technology ...
(Date:8/27/2014)... , Aug. 27, 2014 Reportbuyer.com ... The Graphene Opportunity - A Rational View ... Graphene The New Nanotech? A similar amount ... of applications ranging from microelectronics to water treatment, ... announced the availability of the Graphene Opportunity Report, ...
Breaking Biology Technology:Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4
... , Amsterdam Molecular Therapeutics (Euronext: AMT), ... today that it has filed,a request for re-examination of ... European Medicines Agency.,Glybera is a gene therapy for the ... re-examination of,the dossier will be completed by the end ...
... a combination of sophisticated computer modeling and advanced ... team led by the University at Buffalo (UB) ... Technology (NIST), the Molecular Foundry at Lawrence Berkeley ... relatively simple processing flaws can seriously degrade the ...
... 7, 2011 For the first time since stem ... isolated a human blood stem cell in its purest ... regenerating the entire blood system. This breakthrough opens the ... to treat cancer and other debilitating diseases more effectively. ...
Cached Biology Technology:Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination 2Graphene: What can go wrong? new studies point to wrinkles, process contaminants 2"Pure" Human Blood Stem-Cell Discovery Opens Door to Expanding Cells for More Clinical Use 2"Pure" Human Blood Stem-Cell Discovery Opens Door to Expanding Cells for More Clinical Use 3